Related Experiment Video

Updated: Jun 1, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Neuregulin in heart failure : reverse translation from cancer cardiotoxicity to new heart failure therapy

C A Geisberg1, D J Lenihan

  • 1Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, USA. carrie.geisberg@vanderbilt.edu

Herz
|June 3, 2011
PubMed

Insights

Neuregulin-1 (NRG-1) shows promise for treating heart failure by supporting heart cell survival and function. Further research is needed to understand its cardiac repair mechanisms and safe application.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Oncology

Background:

  • Trastuzumab, an ErbB2-targeting antibody for Her2(+) breast cancer, revealed ErbB2 signaling's cardiac role.
  • Neuregulin-1 (NRG-1) is a stress-induced growth factor crucial for heart protection via ErbB receptor signaling.
  • Disrupted NRG/ErbB signaling impairs normal development and cardiac function in animal models.

Purpose of the Study:

  • To explore the potential of Neuregulin-1 (NRG-1) as a therapeutic agent for heart failure.
  • To investigate the mechanisms underlying NRG-1-mediated cardiac repair.
  • To assess the safety and efficacy of recombinant NRG-1 in treating cardiac conditions.

Main Methods:

  • Review of pre-clinical animal studies on NRG-1 and cardiac function.
  • Analysis of early-phase human studies investigating NRG-1 for heart failure.
  • Examination of ErbB receptor signaling pathways in the context of cardiac stress and repair.

Main Results:

  • Pre-clinical and early human studies suggest recombinant NRG-1 may be a promising therapy for heart failure.
  • NRG-1 signaling is vital for myocyte survival, proliferation, differentiation, hypertrophy, and angiogenesis.
  • Disruption of NRG/ErbB signaling leads to developmental abnormalities and impaired postnatal cardiac function.

Conclusions:

  • Recombinant NRG-1 holds significant therapeutic potential for various forms of heart failure.
  • Understanding the precise mechanisms of cardiac repair driven by NRG-1 is essential.
  • Further investigation is required to establish safe and effective application methods for NRG-1 in heart failure treatment.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...